| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.37 | 0.02 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.3 | 0.03 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.3 | 0.03 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |